The German drug manufacturer announced plans for facility last year, explaining that construction at the site in Chicago’s Melrose Park suburb will help it capture a greater share of the US injectables market.
The project will create several manufacturing suites equipped with automated aseptic filling lines, expanded lyophilization capabilities, and formulation areas, as well as a dedicated warehouse for raw materials.